Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial.

Francois B, Jeannet R, Daix T, Walton AH, Shotwell MS, Unsinger J, Monneret G, Rimmelé T, Blood T, Morre M, Gregoire A, Mayo GA, Blood J, Durum SK, Sherwood ER, Hotchkiss RS.

JCI Insight. 2018 Mar 8;3(5). pii: 98960. doi: 10.1172/jci.insight.98960.

2.

ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients.

Trédan O, Ménétrier-Caux C, Ray-Coquard I, Garin G, Cropet C, Verronèse E, Bachelot T, Rebattu P, E Heudel P, Cassier P, Chabaud S, Croughs T, Dupont P, C Cadore A, Clapisson G, Delgado A, Bardin-Dit-Courageot C, Rigal C, N'Kodia A, Gilles-Afchain L, Morre M, Pérol D, Blay JY, Caux C.

Ann Oncol. 2018 Feb 1;29(2):523. doi: 10.1093/annonc/mdx058. No abstract available.

PMID:
28368453
3.

Interleukin 7 immunotherapy improves host immunity and survival in a two-hit model of Pseudomonas aeruginosa pneumonia.

Shindo Y, Fuchs AG, Davis CG, Eitas T, Unsinger J, Burnham CD, Green JM, Morre M, Bochicchio GV, Hotchkiss RS.

J Leukoc Biol. 2017 Feb;101(2):543-554. doi: 10.1189/jlb.4A1215-581R. Epub 2016 Sep 14.

4.

Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas.

Merchant MS, Bernstein D, Amoako M, Baird K, Fleisher TA, Morre M, Steinberg SM, Sabatino M, Stroncek DF, Venkatasan AM, Wood BJ, Wright M, Zhang H, Mackall CL.

Clin Cancer Res. 2016 Jul 1;22(13):3182-91. doi: 10.1158/1078-0432.CCR-15-2550. Epub 2016 Jan 28.

5.

Treatment with Interleukin-7 Restores Host Defense against Pneumocystis in CD4+ T-Lymphocyte-Depleted Mice.

Ruan S, Samuelson DR, Assouline B, Morre M, Shellito JE.

Infect Immun. 2015 Oct 19;84(1):108-19. doi: 10.1128/IAI.01189-15. Print 2016 Jan.

6.

ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients.

Trédan O, Ménétrier-Caux C, Ray-Coquard I, Garin G, Cropet C, Verronèse E, Bachelot T, Rebattu P, Heudel PE, Cassier P, Chabaud S, Croughs T, Dupont P, Cadore AC, Clapisson G, Delgado A, Bardin-dit-Courageot C, Rigal C, N'Kodia A, Gilles-Afchain L, Morre M, Pérol D, Blay JY, Caux C.

Ann Oncol. 2015 Jul;26(7):1353-62. doi: 10.1093/annonc/mdv173. Epub 2015 Apr 7. Erratum in: Ann Oncol. 2018 Feb 1;29(2):523.

PMID:
25851629
7.

Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation.

Perales MA, Goldberg JD, Yuan J, Koehne G, Lechner L, Papadopoulos EB, Young JW, Jakubowski AA, Zaidi B, Gallardo H, Liu C, Rasalan T, Wolchok JD, Croughs T, Morre M, Devlin SM, van den Brink MR.

Blood. 2012 Dec 6;120(24):4882-91. doi: 10.1182/blood-2012-06-437236. Epub 2012 Sep 25.

8.

Interleukin-7 ameliorates immune dysfunction and improves survival in a 2-hit model of fungal sepsis.

Unsinger J, Burnham CA, McDonough J, Morre M, Prakash PS, Caldwell CC, Dunne WM Jr, Hotchkiss RS.

J Infect Dis. 2012 Aug 15;206(4):606-16. doi: 10.1093/infdis/jis383. Epub 2012 Jun 12.

9.

Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study.

Lévy Y, Sereti I, Tambussi G, Routy JP, Lelièvre JD, Delfraissy JF, Molina JM, Fischl M, Goujard C, Rodriguez B, Rouzioux C, Avettand-Fenoël V, Croughs T, Beq S, Morre M, Poulin JF, Sekaly RP, Thiebaut R, Lederman MM.

Clin Infect Dis. 2012 Jul;55(2):291-300. doi: 10.1093/cid/cis383. Epub 2012 May 1.

10.

Treatment with IL-7 prevents the decline of circulating CD4+ T cells during the acute phase of SIV infection in rhesus macaques.

Vassena L, Miao H, Cimbro R, Malnati MS, Cassina G, Proschan MA, Hirsch VM, Lafont BA, Morre M, Fauci AS, Lusso P.

PLoS Pathog. 2012;8(4):e1002636. doi: 10.1371/journal.ppat.1002636. Epub 2012 Apr 12.

11.

Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival.

Morre M, Beq S.

Target Oncol. 2012 Mar;7(1):55-68. doi: 10.1007/s11523-012-0210-4. Epub 2012 Mar 2. Review.

12.

IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology.

Pellegrini M, Calzascia T, Toe JG, Preston SP, Lin AE, Elford AR, Shahinian A, Lang PA, Lang KS, Morre M, Assouline B, Lahl K, Sparwasser T, Tedder TF, Paik JH, DePinho RA, Basta S, Ohashi PS, Mak TW.

Cell. 2011 Feb 18;144(4):601-13. doi: 10.1016/j.cell.2011.01.011. Epub 2011 Feb 3.

13.

Interleukin-7 treatment counteracts IFN-α therapy-induced lymphopenia and stimulates SIV-specific cytotoxic T lymphocyte responses in SIV-infected rhesus macaques.

Parker R, Dutrieux J, Beq S, Lemercier B, Rozlan S, Fabre-Mersseman V, Rancez M, Gommet C, Assouline B, Rancé I, Lim A, Morre M, Cheynier R.

Blood. 2010 Dec 16;116(25):5589-99. doi: 10.1182/blood-2010-03-276261. Epub 2010 Sep 14.

14.

Interleukin-7 (IL-7) treatment accelerates neutrophil recruitment through gamma delta T-cell IL-17 production in a murine model of sepsis.

Kasten KR, Prakash PS, Unsinger J, Goetzman HS, England LG, Cave CM, Seitz AP, Mazuski CN, Zhou TT, Morre M, Hotchkiss RS, Hildeman DA, Caldwell CC.

Infect Immun. 2010 Nov;78(11):4714-22. doi: 10.1128/IAI.00456-10. Epub 2010 Sep 7.

15.

Increased CD4+ T cell levels during IL-7 administration of antiretroviral therapy-treated simian immunodeficiency virus-positive macaques are not dependent on strong proliferative responses.

Leone A, Rohankhedkar M, Okoye A, Legasse A, Axthelm MK, Villinger F, Piatak M Jr, Lifson JD, Assouline B, Morre M, Picker LJ, Sodora DL.

J Immunol. 2010 Aug 1;185(3):1650-9. doi: 10.4049/jimmunol.0902626. Epub 2010 Jul 9.

16.

IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis.

Unsinger J, McGlynn M, Kasten KR, Hoekzema AS, Watanabe E, Muenzer JT, McDonough JS, Tschoep J, Ferguson TA, McDunn JE, Morre M, Hildeman DA, Caldwell CC, Hotchkiss RS.

J Immunol. 2010 Apr 1;184(7):3768-79. doi: 10.4049/jimmunol.0903151. Epub 2010 Mar 3.

17.

Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy.

Sportès C, Babb RR, Krumlauf MC, Hakim FT, Steinberg SM, Chow CK, Brown MR, Fleisher TA, Noel P, Maric I, Stetler-Stevenson M, Engel J, Buffet R, Morre M, Amato RJ, Pecora A, Mackall CL, Gress RE.

Clin Cancer Res. 2010 Jan 15;16(2):727-35. doi: 10.1158/1078-0432.CCR-09-1303. Epub 2010 Jan 12.

18.

A validated assay to measure soluble IL-7 receptor shows minimal impact of IL-7 treatment.

Janot-Sardet C, Assouline B, Cheynier R, Morre M, Beq S.

J Immunol Methods. 2010 Feb 28;353(1-2):115-23. doi: 10.1016/j.jim.2009.12.003. Epub 2009 Dec 24.

PMID:
20035760
19.

Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies.

Pellegrini M, Calzascia T, Elford AR, Shahinian A, Lin AE, Dissanayake D, Dhanji S, Nguyen LT, Gronski MA, Morre M, Assouline B, Lahl K, Sparwasser T, Ohashi PS, Mak TW.

Nat Med. 2009 May;15(5):528-36. doi: 10.1038/nm.1953. Epub 2009 Apr 26. Erratum in: Nat Med. 2009 Jul;15(7):819.

PMID:
19396174
20.

IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection.

Sereti I, Dunham RM, Spritzler J, Aga E, Proschan MA, Medvik K, Battaglia CA, Landay AL, Pahwa S, Fischl MA, Asmuth DM, Tenorio AR, Altman JD, Fox L, Moir S, Malaspina A, Morre M, Buffet R, Silvestri G, Lederman MM; ACTG 5214 Study Team.

Blood. 2009 Jun 18;113(25):6304-14. doi: 10.1182/blood-2008-10-186601. Epub 2009 Apr 20.

21.

Injection of glycosylated recombinant simian IL-7 provokes rapid and massive T-cell homing in rhesus macaques.

Beq S, Rozlan S, Gautier D, Parker R, Mersseman V, Schilte C, Assouline B, Rancé I, Lavedan P, Morre M, Cheynier R.

Blood. 2009 Jul 23;114(4):816-25. doi: 10.1182/blood-2008-11-191288. Epub 2009 Apr 7.

22.

Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment.

Levy Y, Lacabaratz C, Weiss L, Viard JP, Goujard C, Lelièvre JD, Boué F, Molina JM, Rouzioux C, Avettand-Fénoêl V, Croughs T, Beq S, Thiébaut R, Chêne G, Morre M, Delfraissy JF.

J Clin Invest. 2009 Apr;119(4):997-1007. doi: 10.1172/JCI38052. Epub 2009 Mar 16.

23.

Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets.

Sportès C, Hakim FT, Memon SA, Zhang H, Chua KS, Brown MR, Fleisher TA, Krumlauf MC, Babb RR, Chow CK, Fry TJ, Engels J, Buffet R, Morre M, Amato RJ, Venzon DJ, Korngold R, Pecora A, Gress RE, Mackall CL.

J Exp Med. 2008 Jul 7;205(7):1701-14. doi: 10.1084/jem.20071681. Epub 2008 Jun 23.

24.

Effects of IL-7 on memory CD8 T cell homeostasis are influenced by the timing of therapy in mice.

Nanjappa SG, Walent JH, Morre M, Suresh M.

J Clin Invest. 2008 Mar;118(3):1027-39. doi: 10.1172/JCI32020.

25.

Rapid modifications of peripheral T-cell subsets that express CD127 in macaques treated with recombinant IL-7.

Dereuddre-Bosquet N, Vaslin B, Delache B, Brochard P, Clayette P, Aubenque C, Morre M, Assouline B, Le Grand R.

J Med Primatol. 2007 Aug;36(4-5):228-37.

PMID:
17669211
26.

Expression of IL-7 receptor alpha is necessary but not sufficient for the formation of memory CD8 T cells during viral infection.

Hand TW, Morre M, Kaech SM.

Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11730-5. Epub 2007 Jul 3.

27.

Old rhesus macaques treated with interleukin-7 show increased TREC levels and respond well to influenza vaccination.

Aspinall R, Pido-Lopez J, Imami N, Henson SM, Ngom PT, Morre M, Niphuis H, Remarque E, Rosenwirth B, Heeney JL.

Rejuvenation Res. 2007 Mar;10(1):5-17.

PMID:
17378748
28.

Interleukin-15 but not interleukin-7 abrogates vaccine-induced decrease in virus level in simian immunodeficiency virus mac251-infected macaques.

Hryniewicz A, Price DA, Moniuszko M, Boasso A, Edghill-Spano Y, West SM, Venzon D, Vaccari M, Tsai WP, Tryniszewska E, Nacsa J, Villinger F, Ansari AA, Trindade CJ, Morre M, Brooks D, Arlen P, Brown HJ, Kitchen CM, Zack JA, Douek DC, Shearer GM, Lewis MG, Koup RA, Franchini G.

J Immunol. 2007 Mar 15;178(6):3492-504.

29.

IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells.

Rosenberg SA, Sportès C, Ahmadzadeh M, Fry TJ, Ngo LT, Schwarz SL, Stetler-Stevenson M, Morton KE, Mavroukakis SA, Morre M, Buffet R, Mackall CL, Gress RE.

J Immunother. 2006 May-Jun;29(3):313-9.

30.

Recombinant interleukin-7 induces proliferation of naive macaque CD4+ and CD8+ T cells in vivo.

Moniuszko M, Fry T, Tsai WP, Morre M, Assouline B, Cortez P, Lewis MG, Cairns S, Mackall C, Franchini G.

J Virol. 2004 Sep;78(18):9740-9.

31.

IL-7 stimulates T cell renewal without increasing viral replication in simian immunodeficiency virus-infected macaques.

Nugeyre MT, Monceaux V, Beq S, Cumont MC, Ho Tsong Fang R, Chêne L, Morre M, Barré-Sinoussi F, Hurtrel B, Israël N.

J Immunol. 2003 Oct 15;171(8):4447-53.

32.

Effect of propranolol on growth hormone response to GH releasing hormone (GHRH 1-44) in the dog.

Regnier A, Bret L, Morre M.

Res Vet Sci. 1992 Jan;52(1):110-2.

PMID:
1553429
33.
34.

Growth hormone response induced by synthetic human growth hormone-releasing factor (1-44) in healthy dogs.

Abribat T, Regnier A, Morre M.

Zentralbl Veterinarmed A. 1989 May;36(5):367-73.

PMID:
2521156
35.

High affinity binding sites for basic fibroblast growth factor in rat hepatic plasma membranes.

Gauthier T, Herbert JJ, Maftoun M, Picard C, Morre M.

Life Sci. 1989;44(8):509-16.

PMID:
2564619
37.
38.

Growth hormone (GH) response to a single intravenous injection of synthetic GH-releasing hormone in prepubertal children with growth failure.

Chatelain P, Alamercery Y, Blanchard J, Boissel JP, Evain-Brion D, Morre M, Olivier M, Sizonenko P, Van Vliet G.

J Clin Endocrinol Metab. 1987 Sep;65(3):387-94.

PMID:
3114296
39.

Results of 1-year growth hormone (GH)-releasing hormone-(1-44) treatment on growth, somatomedin-C, and 24-hour GH secretion in six children with partial GH deficiency.

Rochiccioli PE, Tauber MT, Coude FX, Arnone M, Morre M, Uboldi F, Barbeau C.

J Clin Endocrinol Metab. 1987 Aug;65(2):268-74.

PMID:
3110202
40.

Effect of overnight constant infusion of human growth hormone (GH)-releasing hormone-(1-44) on 24-hour GH secretion in children with partial GH deficiency.

Rochiccioli PE, Tauber MT, Uboldi F, Coude FX, Morre M.

J Clin Endocrinol Metab. 1986 Nov;63(5):1100-5.

PMID:
3093519
41.

Benzodiazepine impairs and beta-carboline enhances performance in learning and memory tasks.

Venault P, Chapouthier G, de Carvalho LP, Simiand J, Morre M, Dodd RH, Rossier J.

Nature. 1986 Jun 26-Jul 2;321(6073):864-6.

PMID:
3724846
45.

Allosteric effects of diprobutine on acetylcholine receptors.

Chemouilli P, Heidmann T, Changeux JP, Bachy A, Morre M.

Eur J Pharmacol. 1985 Nov 5;117(2):205-14.

PMID:
3000803
46.

Effect of valproate on brain GABA: comparison with various medium chain fatty acids.

Keane PE, Morre M.

Pharmacol Res Commun. 1985 Jun;17(6):547-55.

PMID:
3927325
47.
48.

EEG effects of i.v. infusion of pentylenetetrazol in rats: a model for screening and classifying antiepileptic compounds.

Santucci V, Fournier M, Keane P, Simiand J, Michaud JC, Morre M, Biziere K.

Psychopharmacology (Berl). 1985;87(3):337-43.

PMID:
3936090
50.

The quinolines PK 8165 and PK 9084 possess benzodiazepine-like activity in vitro but not in vivo.

Keane PE, Simiand J, Morre M.

Neurosci Lett. 1984 Mar 9;45(1):89-93.

PMID:
6145125

Supplemental Content

Support Center